Takeda Pharmaceutical Co Ltd (TAK)
13.27
+0.08
(+0.61%)
USD |
NYSE |
May 02, 16:00
13.28
0.00 (0.00%)
Pre-Market: 20:00
Takeda Pharmaceutical Cash from Investing (Quarterly): -460.58M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -460.58M |
| September 30, 2023 | -322.20M |
| June 30, 2023 | -1.942B |
| March 31, 2023 | -3.300B |
| December 31, 2022 | -313.42M |
| September 30, 2022 | -151.60M |
| June 30, 2022 | -730.96M |
| March 31, 2022 | -247.48M |
| December 31, 2021 | -578.38M |
| September 30, 2021 | -295.38M |
| June 30, 2021 | -643.58M |
| March 31, 2021 | 2.753B |
| December 31, 2020 | 693.45M |
| September 30, 2020 | 259.79M |
| June 30, 2020 | 6.152M |
| March 31, 2020 | 334.60M |
| December 31, 2019 | -727.37M |
| September 30, 2019 | 3.459B |
| June 30, 2019 | -378.52M |
| March 31, 2019 | -11.26B |
| December 31, 2018 | -14.30B |
| September 30, 2018 | 137.47M |
| June 30, 2018 | -156.69M |
| March 31, 2018 | -968.00M |
| December 31, 2017 | -83.55M |
| Date | Value |
|---|---|
| September 30, 2017 | -684.96M |
| June 30, 2017 | 894.05M |
| March 31, 2017 | -5.696B |
| December 31, 2016 | -258.79M |
| September 30, 2016 | -56.13M |
| June 30, 2016 | -51.98M |
| March 31, 2016 | 223.83M |
| December 31, 2015 | -482.31M |
| September 30, 2015 | -167.11M |
| June 30, 2015 | -167.81M |
| March 31, 2015 | -69.13M |
| December 31, 2014 | 659.36M |
| September 30, 2014 | -43.69M |
| June 30, 2014 | 288.79M |
| March 31, 2014 | -110.98M |
| December 31, 2013 | -1.280B |
| September 30, 2013 | 16.42M |
| June 30, 2013 | -163.30M |
| March 31, 2011 | -21.14M |
| December 31, 2010 | -403.51M |
| September 30, 2010 | -497.71M |
| June 30, 2010 | -230.38M |
| March 31, 2010 | -600.29M |
| December 31, 2009 | -248.53M |
| September 30, 2009 | -187.37M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-3.300B
Minimum
Mar 2023
3.459B
Maximum
Sep 2019
-136.10M
Average
-313.42M
Median
Dec 2022
Cash from Investing (Quarterly) Benchmarks
| Hoya Corp | -47.92M |
| Astellas Pharma Inc | -155.23M |
| Nxera Pharma Co Ltd | -18.93M |
| PeptiDream Inc | -3.046M |
| Stemcell Holdings Inc | -0.1868M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 948.05M |
| Cash from Financing (Quarterly) | -632.25M |
| Free Cash Flow | -814.80M |
| Free Cash Flow Per Share (Quarterly) | 0.15 |
| Free Cash Flow to Equity (Quarterly) | -1.274B |
| Free Cash Flow to Firm (Quarterly) | 1.000B |
| Free Cash Flow Yield | -1.95% |